OR WAIT null SECS
On Wednesday, Oct. 9, 2018, Dr. Caroline Bauer will discuss selecting technologies that enable the progression of compounds that require bioavailability enhancement to achieve target absorption at CPhI Worldwide.
On Tuesday, Oct. 9, 2018, Dr. Caroline Bauer, pharmaceutical development manager at the Lonza Ploermel site in France, will discuss selecting technologies that enable the progression of compounds that require bioavailability enhancement to achieve target absorption at CPhI Worldwide in Madrid, Spain.
The presentation, “Technology Selection Methodologies for Addressing Bioavailability Challenges,” will focus on the rationale for selecting technologies that enable progression of such compounds, based on compound’s physical properties (e.g. melt and glass-transition temperatures, Log P) and product specifications (e.g., dose, pharmacokinetics, permeability). Predictive modeling and rapid screening best practices will also be discussed, along with representative case studies.
Prior to joining Lonza, Bauer worked for a biotechnology company in the field of innovative drug-delivery systems. In her current role, she deals with pharmaceutical development projects ranging from early- to late-stage development for new chemical entity, lifecycle management, as well as generic drug development.
The briefing will take place from 3:10–3:40pm at the ICSE Theatre, Hall 1, stand 1G90.